On March 18, 2026, Intelligent Bio Solutions Inc. announced the approval of time-vesting and performance-vesting restricted stock awards for its executives and directors. The Board of Directors, upon the recommendation of the Compensation Committee, granted a total of 39,650 shares of the Company’s Common Stock to key personnel, including the Chief Executive Officer, Harry Simeonidis, and Chief Financial Officer, Spiro Sakiris. Each executive received 9,150 time-vesting shares, which will vest over a period of 48 months, contingent upon their continued service with the Company. Additionally, both executives were awarded 21,350 performance-vesting shares, which will vest based on the achievement of specific performance milestones related to clinical trials and regulatory submissions.

The Company also approved the issuance of 20,000 shares to non-employee directors, which will vest after 12 months, further aligning the interests of the board with those of shareholders. This move is seen as a strategic effort to retain top talent and incentivize performance, particularly as the Company navigates its growth trajectory in the biotechnology sector.

As of March 23, 2026, the total number of outstanding shares of the Company’s Common Stock was reported at 2,001,173 shares. The Company has also entered into an At The Market Offering Agreement, allowing it to sell additional shares to raise capital as needed. This financing strategy is expected to provide the necessary liquidity to support ongoing operations and future growth initiatives. The combination of stock awards and the ATM offering reflects a proactive approach to managing both talent and financial resources effectively.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.